What's in Azurity Pharmaceuticals's pipeline?

Azurity Pharmaceuticals has 6 drugs in our index: 6 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Azurity Pharmaceuticals's portfolio?

Top competitors by shared drug class: , Pfizer, Recordati, Novartis, Merck & Co..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/azurity.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Azurity Pharmaceuticals — Portfolio Competitive Intelligence Brief

Azurity Pharmaceuticals (PRIVATE) pipeline: 6 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

PRIVATE (Private) 6 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Horizant	GABAPENTIN ENACARBIL	marketed	Anti-epileptic Agent	Voltage-dependent calcium channel subunit alpha-2/delta-1	Neuroscience	2011-01-01
Sular	NISOLDIPINE	marketed	Dihydropyridine Calcium Channel Blocker [EPC]	Voltage-dependent L-type calcium channel subunit alpha-1C	Cardiovascular	1995-01-01
Vasotec	ENALAPRIL MALEATE	marketed	Angiotensin Converting Enzyme Inhibitor	Angiotensin-converting enzyme	Cardiovascular	1985-01-01
Testosterone Cypionate	Testosterone Cypionate	marketed	Androgen	Androgen receptor	Oncology	1978-01-01
Gleostine	LOMUSTINE	marketed	Alkylating Drug [EPC]		Oncology	1976-01-01
Amphetamine Sulfate	AMPHETAMINE SULFATE	marketed	Central Nervous System Stimulant	Sodium-dependent dopamine transporter	Metabolic	1955-01-01

Therapeutic area mix

Cardiovascular · 2
Oncology · 2
Metabolic · 1
Neuroscience · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

· 4 shared drug classes
Pfizer · 3 shared drug classes
Recordati · 2 shared drug classes
Novartis · 2 shared drug classes
Merck & Co. · 2 shared drug classes
Endo · 1 shared drug class
Chiesi · 1 shared drug class
Baxter · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Azurity Pharmaceuticals:

Cite this brief

Drug Landscape (2026). Azurity Pharmaceuticals — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/azurity. Accessed 2026-05-13.